Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond.

Chan JJ, Tan TJY, Dent RA.

Ther Adv Med Oncol. 2019 Oct 9;11:1758835919880429. doi: 10.1177/1758835919880429. eCollection 2019. Review.

2.

What is the role of immunotherapy in breast cancer?

Tan TJ, Chan JJ, Kamis S, Dent RA.

Chin Clin Oncol. 2018 Apr;7(2):13. doi: 10.21037/cco.2018.04.01. Review.

3.

Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?

Chan JJ, Tan TJY, Dent RA.

J Oncol Pract. 2018 May;14(5):281-289. doi: 10.1200/JOP.18.00034.

PMID:
29746805
4.

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma.

Lee JJX, Chan JJ, Choo SP.

Diseases. 2015 Oct 28;3(4):306-324. doi: 10.3390/diseases3040306. Review.

5.

Coexistence of unicentric Castleman's Disease and locally advanced papillary renal cell carcinoma: More than a coincidental association?

Chan JJ, Loh AH, Sim HG, Tan MH, Toh CK.

Ann Acad Med Singapore. 2010 Jul;39(7):584-2. No abstract available.

Supplemental Content

Loading ...
Support Center